KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Shares Outstanding (2016 - 2025)

NovoCure (NVCR) has disclosed Shares Outstanding for 12 consecutive years, with $112.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 3.66% to $112.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.5 million through Dec 2025, up 3.66% year-over-year, with the annual reading at $112.5 million for FY2025, 3.66% up from the prior year.
  • Shares Outstanding hit $112.5 million in Q4 2025 for NovoCure, roughly flat from $112.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $112.5 million in Q4 2025 to a low of $103.2 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $107.0 million across 5 years, with a median of $106.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding: increased 1.04% in 2022 and later grew 3.66% in 2025.
  • Year by year, Shares Outstanding stood at $104.0 million in 2021, then grew by 1.04% to $105.0 million in 2022, then increased by 1.93% to $107.1 million in 2023, then rose by 1.35% to $108.5 million in 2024, then rose by 3.66% to $112.5 million in 2025.
  • Business Quant data shows Shares Outstanding for NVCR at $112.5 million in Q4 2025, $112.0 million in Q3 2025, and $111.8 million in Q2 2025.